Fudan University

Bio-Thera Solutions' BAT4406F, an ADCC-enhanced anti-CD20 monoclonal antibody, demonstrated statistically significant efficacy in treating neuromyelitis optica spectrum disorder (NMOSD) during interim analysis of its pivotal Phase II/III trial.

Singlera Genomics and Fudan University's Zhongshan Hospital published results from the GUIDE prospective cohort study in Molecular Cancer, demonstrating their GutSeer assay's ability to detect five major gastrointestinal cancers through a simple blood test.

A novel multimodal fusion (MMF) system combining CT imaging-based deep learning with clinical features achieved C-index values of 0.74 for overall survival and 0.69 for progression-free survival in predicting outcomes for unresectable hepatocellular carcinoma patients receiving immune checkpoint inhibitors.

Finnish longitudinal study reveals children with higher physical fitness levels develop better cognitive abilities and experience lower rates of depression and stress as teenagers.

A phase 2 trial demonstrates manageable safety profile of serplulimab combined with bevacizumab biosimilar HLX04 as first-line treatment for advanced hepatocellular carcinoma.

The NSABP B-59 trial showed that adding atezolizumab to neoadjuvant chemotherapy did not significantly improve event-free survival in stage II-III TNBC.

Wegovy, a weight-loss drug containing semaglutide, has been introduced in China, offering a new treatment option for the country's increasing obese population.